• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高血压患者中依那普利所致干咳继发发展的药物遗传学预测因素。

Pharmacogenetic predictors of development of secondary to enalapril dry cough in hypertensive patients.

作者信息

Sychev Ivan V, Denisenko Natalia P, Kachanova Anastasiya A, Lapshtaeva Anna V, Goncharova Ludmila N, Mirzaev Karin B, Sychev Dmitry A

机构信息

Department of Faculty Therapy with Courses of Physiotherapy, Physical Therapy, Ogarev Mordovia State University, Saransk, Russian Federation.

68, Bolshevitskaya Street, Saransk, Republic of Mordovia, 430005, Russia.

出版信息

Drug Metab Pers Ther. 2023 May 19;38(3):247-254. doi: 10.1515/dmpt-2023-0008. eCollection 2023 Sep 1.

DOI:10.1515/dmpt-2023-0008
PMID:37201212
Abstract

OBJECTIVES

Development of the secondary to ACEI cough leads to discontinuation of the drugs of this group. Assessing the safety of the ACEIs with further development of customized approaches for their administration is a major scientific and practical problem. The objective of this study was to assess the association of the genetic markers with the development of the adverse drug reaction in the form of secondary to enalapril dry cough in the patients with essential arterial hypertension.

METHODS

Study involved 113 patients with the secondary to enalapril cough and 104 patients without development of the secondary to enalapril adverse drug reaction.

RESULTS

The patients carriers of the genotype AA rs2306283 of gene SLCO1B1 had 2-fold higher odds of developing the dry cough than those with the genotypes AG and GG (ОR=2.01, 95%CI=1.10-3.66, р=0.023). Similarly, the patients heterozygous for rs8176746 of gene АВО had 2.3-fold higher odds of developing the ADR in the form of dry cough than the carriers of the genotypes GG and TT (ОR=2.30, 95%CI=1.24-4.29, р=0.008).

CONCLUSIONS

Statistically significant association between the development of the ADR in the form of secondary to enalapril dry cough and polymorphisms rs2306283 of gene SLCO1B1 and rs8176746 of gene ABO was revealed.

摘要

目的

血管紧张素转换酶抑制剂(ACEI)引发的咳嗽会导致该类药物停用。随着ACEI给药定制方法的进一步发展,评估其安全性是一个重大的科学和实际问题。本研究的目的是评估基因标记与原发性高血压患者中依那普利引发的干咳形式的药物不良反应发生之间的关联。

方法

研究纳入了113例出现依那普利引发咳嗽的患者和104例未出现依那普利药物不良反应的患者。

结果

基因SLCO1B1的rs2306283基因型为AA的患者发生干咳的几率比基因型为AG和GG的患者高2倍(比值比[OR]=2.01,95%置信区间[CI]=1.10 - 3.66,p = 0.023)。同样,基因ABO的rs8176746杂合子患者发生干咳形式药物不良反应的几率比基因型为GG和TT的携带者高2.3倍(OR = 2.30,95%CI = 1.24 - 4.29,p = 0.008)。

结论

揭示了依那普利引发的干咳形式的药物不良反应发生与基因SLCO1B1的rs2306283多态性和基因ABO的rs8176746之间具有统计学意义的关联。

相似文献

1
Pharmacogenetic predictors of development of secondary to enalapril dry cough in hypertensive patients.高血压患者中依那普利所致干咳继发发展的药物遗传学预测因素。
Drug Metab Pers Ther. 2023 May 19;38(3):247-254. doi: 10.1515/dmpt-2023-0008. eCollection 2023 Sep 1.
2
Pharmacogenetic markers of development of angioneurotic edema as a secondary side effect to enalapril in patients with essential arterial hypertension.血管神经性水肿作为依那普利治疗原发性动脉高血压的继发副作用的药物遗传学标志物。
Int J Risk Saf Med. 2024;35(1):37-47. doi: 10.3233/JRS-230006.
3
Rs495828 polymorphism of the ABO gene is a predictor of enalapril-induced cough in Chinese patients with essential hypertension.ABO 基因的 Rs495828 多态性是预测中国原发性高血压患者依那普利诱导咳嗽的标志物。
Pharmacogenet Genomics. 2014 Jun;24(6):306-13. doi: 10.1097/FPC.0000000000000050.
4
SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril)-Induced Cough: a Pharmacogenetic Study.溶质载体有机阴离子转运体家族1成员B1(SLCO1B1)基因变异与血管紧张素转换酶抑制剂(依那普利)所致咳嗽:一项药物遗传学研究
Sci Rep. 2015 Nov 26;5:17253. doi: 10.1038/srep17253.
5
Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough: the role of ACE, ABO, and BDKRB2 genes.血管紧张素转换酶抑制剂诱发咳嗽的药物遗传学预测因子:ACE、ABO 和 BDKRB2 基因的作用。
Pharmacogenet Genomics. 2011 Sep;21(9):531-8. doi: 10.1097/FPC.0b013e328348c6db.
6
Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Multicentre Cough Study Group.坎地沙坦酯对依那普利所致咳嗽的高血压患者无咳嗽相关性。多中心咳嗽研究组。
Am J Hypertens. 2000 Feb;13(2):214-8. doi: 10.1016/s0895-7061(99)00165-x.
7
[A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].[纳曲酮与胍法辛联合治疗阿片类成瘾者中多巴胺能和阿片样物质能基因的药物遗传学分析]
Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(11. Vyp. 2):36-48. doi: 10.17116/jnevro201611611236-48.
8
Enalapril-induced cough.依那普利引起的咳嗽。
Arch Intern Med. 1989 Dec;149(12):2701-3.
9
Persistent dry cough with enalapril: incidence depends on method used.依那普利引起的持续性干咳:发生率取决于所采用的方法。
J Hum Hypertens. 1990 Oct;4(5):517-20.
10
Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo.抗高血压治疗中的生活质量与咳嗽:依普罗沙坦、依那普利和安慰剂的随机试验
J Hum Hypertens. 2001 Dec;15(12):863-7. doi: 10.1038/sj.jhh.1001283.

引用本文的文献

1
Association of gene variants with angiotensin-converting enzyme inhibitor-induced cough in a Pakistani hypertensive cohort.巴基斯坦高血压队列中基因变异与血管紧张素转换酶抑制剂引起的咳嗽的关联
Front Pharmacol. 2024 Sep 4;15:1441251. doi: 10.3389/fphar.2024.1441251. eCollection 2024.
2
Clinical Significance and Patterns of Potential Drug-Drug Interactions in Cardiovascular Patients: Focus on Low-Dose Aspirin and Angiotensin-Converting Enzyme Inhibitors.心血管疾病患者潜在药物相互作用的临床意义及模式:聚焦小剂量阿司匹林与血管紧张素转换酶抑制剂
J Clin Med. 2024 Jul 23;13(15):4289. doi: 10.3390/jcm13154289.